title: Punica granatum (pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicide.
abstract: For approximately 24 years the AIDS pandemic has claimed approximately 30 million lives, causing approximately 14,000 new HIV-1 infections daily worldwide in 2003. About 80% of infections occur by heterosexual transmission. In the absence of vaccines, topical microbicides, expected to block virus transmission, offer hope for controlling the pandemic. Antiretroviral chemotherapeutics have decreased AIDS mortality in industrialized countries, but only minimally in developing countries. To prevent an analogous dichotomy, microbicides should be acceptable, accessible, affordable, and accelerative in transition from development to marketing. Already marketed pharmaceutical excipients (inactive materials of drug dosage forms) or foods, with established safety records and adequate anti-HIV-1 activity, may provide this option. Therefore, fruit juices were screened for inhibitory activity against HIV-1 IIIB using CD4 and CXCR4 as cell receptors. The best juice was tested for inhibition of: (1) infection by HIV-1 BaL, utilizing CCR5 as the cellular coreceptor, and (2) binding of gp120 IIIB and gp120 BaL, respectively, to CXCR4 and CCR5. To remove most colored juice components, the adsorption of the effective ingredient(s) to dispersible excipients and other foods was investigated. A selected complex was assayed for inhibition of infection by primary HIV-1 isolates. The results indicate that HIV-1 entry inhibitors from pomegranate juice adsorb onto corn starch. The resulting complex blocks virus binding to CD4 and CXCR4/CCR5 and inhibits infection by primary virus clades A to G and group O. Therefore, these results suggest the possibility of producing an anti-HIV-1 microbicide from inexpensive, widely available sources, whose safety has been established throughout centuries, provided that its quality is adequately standardized and monitored.
authors.affiliation: New York Blood Center, New York, NY 10021, USA. arneurath@att.net
authors.forename: A Robert
authors.initials: AR
authors.lastname: Neurath
authors.forename: Nathan
authors.initials: N
authors.lastname: Strick
authors.forename: Yun-Yao
authors.initials: YY
authors.lastname: Li
authors.forename: Asim K
authors.initials: AK
authors.lastname: Debnath
mesh_terms: D015704:CD4 Antigens / Q000502:physiology; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D029561:Lythraceae; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology*; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors / Q000502:physiology; D015728:Receptors, HIV / Q000037:antagonists & inhibitors
chemical_list: D015704:CD4 Antigens; D010936:Plant Extracts; D019718:Receptors, CXCR4; D015728:Receptors, HIV